Singapore – MP Biomedicals launches Rapid SARS-CoV-2 Antigen Test Cards in Asia Pacific (APAC) region to meet increasing demand for antigen testing following resurgence of Covid-19 cases as the delta variant strains make new waves across the countries in the APAC region.
MP Biomedicals Rapid SARS-CoV-2 Antigen Test Card detects the SARS-CoV-2 nucleocapsid protein (N protein). So, theoretically, the important and current SARS-CoV-2 variants which carry non-nucleocapsid protein mutations such as spike proteins do not affect the product performance.
MP Biomedicals launches two versions of Rapid SARS-CoV-2 Antigen Test Cards:
- CE marked; 20 tests per kit
- Fast and Convenient: Results available in 15 minutes. Requires no instrument.
- Easy to use: Easy specimen collection with either nasal, nasopharyngeal or oropharyngeal swab
- Excellent performance results:
- Specificity 99.16%
- Sensitivity 96.17%
- Accuracy 98.25%
Intended for use by any lab or healthcare professionals, the rapid antigen test card produces accurate results in as little as 15 mins. It is developed for point-of-care testing without the need for laboratory instruments or specialized lab personnel to administer the test. The test can be easily administered through nasopharyngeal, oropharyngeal or nasal swab method with similar results.
- CE approved; 1 test per kit
- Fast Results in 15 minutes
- Convenient self-testing:
- Easy self-collection with anterior nasal swab (about 2.5cm into each nose)
- Easy to read results
- Excellent performance results:
- Specificity 99.20%
- Sensitivity 96.77%
- Accuracy 98.72%
The antigen rapid test card for Self-Test use can be easily used by consumers (untrained or lay-users) to check themselves for active SARS-CoV-2 infection.
The self-test card or do-it-yourself (DIY) test card comes with easy-to-follow step-by-step instructional guide and videos to guide the consumers. Consumers would just need to follow the instructions to collect their nasal swab samples from inside of their nose and then perform the test themselves. The test results can be read quickly in 15-20 mins and can be easily interpreted as it employs a lateral flow format like those used in home pregnancy tests.
In countries with the self-test cards, they can be purchased at pharmacies or are employed by companies in industries at high-risk like airlines, shipyards and hotels to get their employees to do self-test on regular basis until their staffs are fully protected with vaccinations.
“With new waves of Covid-19 cases spreading across countries, especially in South-east Asia region, we see the need for fast and reliable rapid testing to quickly cope with the testing demand so as to identify and isolate infected individuals, and therefore help to control the spread of Covid-19.” said Mr Choo Beng Kuan, Director, Sales and Marketing for APAC region at MP Biomedicals.
“Both versions of rapid antigen test cards have been launched and used in European countries with great success during the earlier waves of Covid-19. In APAC, we have received requests from our channels in various countries including Australia, Taiwan, Singapore, Malaysia, Thailand, Indonesia, Vietnam, Cambodia and others and we will be registering and launching both versions to meet the testing demands and to cater to the move to both antigen rapid testing and self-testing approaches to complement PCR testing in Covid-19 monitoring. We hope to achieve similar success in APAC,” he added.
In addition to the Rapid SARS-CoV 2 Antigen Test Cards, MP Biomedicals offers Assure™ SARS-CoV-2 IgM and IgG antibody rapid test (CE) to help with confirming the presence of antibodies linked to positive or past infection of Covid-19. We also offer a range of SARS-CoV-2 antigen and antibody proteins and biochemicals as components for research and manufacturing of Covid-19 in-vitro diagnostic (IVD) products.
About MP Biomedicals:
MP Biomedicals, is a global corporation developing, manufacturing and distributing products for the life science, in vitro diagnostics (IVD) and fine chemicals. Through our global operational network, we provide the research, healthcare and industrial communities with innovative, quality tools to aid in research for groundbreaking discoveries and disease control.
For more information about MP Biomedicals, please visit this link: